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ABSTRACT
Previous studies have shown that the translation
level of in vitro transcribed messenger RNA
(mRNA) is enhanced when its uridines are replaced
with pseudouridines; however, the reason for this
enhancement has not been identified. Here, we
demonstrate that in vitro transcripts containing
uridine activate RNA-dependent protein kinase
(PKR), which then phosphorylates translation initi-
ation factor 2-alpha (eIF-2a), and inhibits translation.
In contrast, in vitro transcribed mRNAs containing
pseudouridine activate PKR to a lesser degree, and
translation of pseudouridine-containing mRNAs is
not repressed. RNA pull-down assays demonstrate
that mRNA containing uridine is bound by PKR more
efficiently than mRNA with pseudouridine. Finally,
the role of PKR is validated by showing that pseudo-
uridine- and uridine-containing RNAs were
translated equally in PKR knockout cells. These
results indicate that the enhanced translation of
mRNAs containing pseudouridine, compared to
those containing uridine, is mediated by decreased
activation of PKR.
INTRODUCTION
In vitro transcribed messenger RNA (mRNA) has many
advantages as a vehicle for gene delivery. Transfection of
mRNA is very eﬃcient (1), and rapid expression of the
encoded protein can be achieved. Unlike viral vectors or
plasmid DNA, cell-delivered mRNA does not introduce
the risk of insertional mutagenesis (2,3). Previous studies
have shown that RNA can activate a number of innate
immune receptors, including Toll-like receptor (TLR)3,
TLR7, TLR8 and retinoic acid-inducible gene I (RIG-I).
However, activation of these receptors can be avoided by
incorporating modiﬁed nucleosides, e.g. pseudouridine
() or 2-thiouridine (s2U), into the RNA (4,5).
RNA-dependent protein kinase (PKR) is a ubiquitous
mammalian enzyme with a variety of cellular functions,
including regulation of translation during conditions of
cell stress. During viral infection, PKR binds viral
double-stranded (ds)RNA, autophosphorylates and sub-
sequently phosphorylates the alpha subunit of translation
initiation factor 2 (eIF-2a), thus repressing translation
(6,7). Originally, potent activation of PKR was thought
to require >30-bp-long dsRNA (8). It has subsequently
been shown that PKR can be activated by a variety of
RNA structures that include single-stranded (ss)RNA
forming hairpins (9,10), imperfect dsRNA containing
mismatches (10), short dsRNA with ss tails (11), stem–
loop structures with 50-triphosphates (12,13), and unique
elements present in interferon gamma (IFN-g) and tumor
necrosis factor-alpha mRNAs (14). Viral (15,16) and
cellular RNAs (17–20) transcribed as ssRNA but contain-
ing secondary structure can also be potent PKR activa-
tors. PKR activation by short dsRNA, such as siRNA,
has also been demonstrated (21–26). These reports
indicate that a wide variety of RNA structures can
activate PKR, provided they contain some dsRNA
element. Modiﬁed nucleosides present in homopolymeric
RNAs (27–30) or in short transcripts (25,31,32) can inﬂu-
ence activation of PKR. However, it has not been
investigated whether modiﬁed nucleosides present in
long, protein-encoding mRNAs impact activation of
PKR.
Previously, we demonstrated that in vitro transcribed
mRNAs containing  are translated at signiﬁcantly
higher levels than those containing unmodiﬁed uridines
(33). However, the molecular mechanism underlying this
enhancement has not been identiﬁed. Here, we show that
one cause of this translational diﬀerence is that
-containing mRNA activates PKR less eﬃciently than
uridine-containing mRNA. This reduced PKR activation
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proteins that is induced when unmodiﬁed in vitro
transcribed mRNAs are delivered to cells. Since replacing
uridines with pseudouridines also abrogates innate
immune activation by RNA, -modiﬁed mRNAs are at-
tractive vectors for gene delivery or replacement, vaccine
antigen delivery or other RNA-based therapeutic
applications.
MATERIALS AND METHODS
Cells and reagents
Human embryonic kidney (HEK) 293T cells were
obtained from the American Type Culture Collection
and were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 2mM L-glutamine
(Life Technologies), 100U/ml penicillin and 100mg/ml
streptomycin (Invitrogen) and 10% fetal calf serum
(HyClone). Immortalized wild-type (WT) and PKR
knockout (PKR
 /–) mouse embryonic ﬁbroblasts
(MEFs) were generously provided by Robert Silverman
(Cleveland Clinic Foundation) and were maintained in
RPMI medium supplemented with 2mM L-glutamine,
100U/ml penicillin, 100mg/ml streptomycin and 10%
fetal calf serum. Polyinosinic:polycytidylic acid
(poly(I:C)) was purchased from Sigma and polydeoxy-
cytidylic acid (poly(dC)) was purchased from Midland
Certiﬁed Reagent Co.
mRNA synthesis
RNAs were transcribed as previously described (4), using
linearized plasmids encoding ﬁreﬂy luciferase (pT7TS-
fLuc and pTEVluc) or Renilla luciferase (pT7TS-Ren)
and T7 RNA polymerase (Megascript, Ambion). Except
where otherwise speciﬁed, capped mRNA was generated
by performing transcription in the presence of cap analog
30-O-Me-m7G(50)ppp(50)G (New England Biolabs). All
mRNAs were transcribed to contain 30 or 50-nt-long 30
poly(A) tails. Triphosphate-derivatives of , s2U, m5C,
m6A and m5U (TriLink) were used in place of their
cognate unmodiﬁed NTP to generate modiﬁed
nucleoside-containing RNA. Following transcription, the
template plasmids were digested with Turbo DNase and
RNAs were precipitated with 2.5M lithium chloride at
 20 C for 4h. RNAs were pelleted by centrifugation,
washed with 75% ethanol and then reconstituted in
nuclease-free water. The concentration of RNA was
determined by measuring the optical density at 260nm.
All RNA samples were analyzed by denaturing agarose
gel electrophoresis for quality assurance. Each RNA
type was synthesized in 4–10 independently performed
transcription experiments and all experiments were per-
formed with at least two diﬀerent batches of mRNA.
Enzymatic capping was performed using ScriptCap m
7G
capping kit (Epicentre) on mRNA transcribed with
guanosine 50-[g-
32P]-triphosphate (GE Healthcare).
Eﬃciency of capping was veriﬁed by monitoring the elim-
ination of g-
32P from the mRNA. Biotinylated mRNA
was transcribed with the addition of 1:5 biotinylated
CTP (Roche Applied Sciences) in the transcription
reaction.
Detection of reporter proteins in RNA-transfected cells
Cells were seeded into 96-well plates at a density of
5.0 10
4 cells/well 1 day prior to transfection. RNA was
complexed with lipofectin (Invitrogen) as described previ-
ously (4). Cells were exposed to 50ml DMEM containing
lipofectin-complexed RNA (0.25mg) for 1h, which was
then replaced with complete medium and further
cultured. Cells were lysed in 25ml ﬁreﬂy, Renilla,o r
dual-luciferase speciﬁc lysis reagents (Promega). Aliquots
of 2ml were assayed with the corresponding enzyme sub-
strates and a LUMAT LB 950 luminometer (Berthold) at
a 10-s measuring time.
Assessment of total protein synthesis
HEK293T cells were seeded into 96-well plates at a density
of 5.0 10
4 cells/well with 1000U/ml interferon-aA/D
(Sigma) 1 day prior to transfection. Cells were incubated
in methionine/cysteine-free medium (Invitrogen) for 1h,
then pulsed with complete medium supplemented with
35S-methionine/cysteine (140 mCi/ml) (PerkinElmer) for
1–3h. Cells were lysed in RIPA lysis buﬀer supplemented
with protease inhibitor cocktail (Sigma). Lysate was
diluted in 0.1% bovine serum albumin (BSA), and macro-
molecules were precipitated by the addition of trichloro-
acetic acid (TCA) and 30min incubation on ice.
Precipitates were ﬁltered onto glass microﬁber ﬁlters
(Whatman) and washed with 10% TCA and 100%
ethanol. Incorporated
35S-methionine/cysteine was
quantiﬁed using Ecolite(+) scintillation cocktail (MP
Biomedicals) and a Beckman LS 6000IC scintillation
counter.
PKR activation in vitro
Puriﬁed PKR prepared as described (11) was
dephosphorylated using lambda protein phosphatase
(New England Biolabs). Final concentrations of 0.75mM
dephosphorylated PKR, 0.1mM ATP and 0.15mCi/ml ad-
enosine 50-[g-
32P]-triphosphate (g-
32P-ATP) (PerkinElmer)
were mixed with the indicated concentration of RNA for
10min at 30 C in a buﬀer consisting of 4mM MgCl2,
100mM KCl and 20mM HEPES, pH 7.5. The reaction
was stopped by the addition of NuPage LDS sample
buﬀer and reducing agent (Invitrogen) and heating for
10min at 70 C. Unincorporated g-
32P-ATP was separated
from radiolabeled PKR by running samples on a 12%
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS–PAGE) gel. Phosphorylated PKR was imaged in
dried gels using a phosphor storage screen (Molecular
Dynamics) and detected using Storm or Typhoon
Phosphorimagers (GE Healthcare). Band densities were
quantiﬁed using ImageQuant software (GE Healthcare).
Western blotting
HEK293T cells were seeded into 96-well plates at a density
of 5.0 10
4 cells/well, with 1000U/ml interferon-aA/D 1
day prior to transfection. At the indicated time following
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supplemented with protease inhibitor cocktail and
HALT phosphatase inhibitor (Pierce). Equal mass of
protein (10 30mg per sample) was loaded onto a 12%
SDS–PAGE gel. Proteins were subsequently transferred
to a Hybond-P polyvinylidene ﬂuoride (PVDF)
membrane (GE Amersham), blocked with 2.5% non-fat
milk in TBS containing 0.05% Tween-20, and probed with
antibodies for PKR-pT446 and PKR (Epitomics),
eIF-2a-pS51 and eIF-2a (Cell Signaling Technologies),
or PABP (Abcam). Membranes were stripped by agitating
gently in a buﬀer of 2% SDS, 100mM b-mercaptoethanol,
62.5mM Tris pH 6.7 for 30min at 50 C, then subsequent-
ly re-blocked and re-probed. Image was captured using the
Fujiﬁlm LAS1000 digital imaging system. Linear bright-
ness and contrast were adjusted using GIMP 2.6 software.
Biotinylated RNA pull-down
HEK293T cells were lysed in RIPA lysis buﬀer supple-
mented with protease inhibitor cocktail and RNase inhibi-
tor (RNasin, Promega). Biotinylated mRNA (2mg) was
added to 25ml lysate and incubated on ice for 2h.
Subsequently, 50ml of streptavidin-agarose bead 50%
slurry (Invitrogen) was added and incubated on ice for
1h. Beads with bound RNA and proteins were centrifuged
and washed, and proteins were released from RNA by
heating samples at 70 C for 10min in the presence of
NuPage LDS sample buﬀer and reducing agent. Samples
were separated by 10% SDS–PAGE and transferred to
PVDF membranes. PKR and poly(A)-binding protein
(PABP) were detected by western blotting.
Statistical analysis
All data are reported as mean±standard error of the
mean (SEM). Statistical diﬀerences between treatment
groups were calculated by the Student’s t-test using
Microsoft Excel. For all statistical testing, a P-value
<0.05 was considered signiﬁcant.
RESULTS
Conventional in vitro transcribed mRNA induces
translational repression
We previously reported that mRNA transcribed in vitro
containing  in place of uridine is translated more eﬃ-
ciently than mRNA containing unmodiﬁed nucleosides
(33). In order to determine whether the translational en-
hancement exerted by  incorporated into RNA is re-
stricted to the modiﬁed transcript or also extends to
unmodiﬁed transcripts, we performed co-transfection ex-
periments delivering equal amounts of Renilla and ﬁreﬂy
luciferase-encoding mRNAs to cells. As expected, the
mRNAs were translated much more eﬃciently when
both contained  as compared to when both were un-
modiﬁed (Figure 1A). However, when only one of the
mRNAs contained  modiﬁcation, the translation level
of the -containing RNA decreased ( 50%) relative to
the level measured when both contained . One explan-
ation for these ﬁndings could be that unmodiﬁed RNA
inhibits the translation of the co-delivered RNA, while
-containing RNA has no such inhibitory eﬀect. To
explore whether translation of endogenous cellular
mRNAs are similarly inﬂuenced by exogenously delivered
in vitro transcribed mRNAs, total cellular protein synthe-
sis was monitored in cells transfected with mRNA con-
taining  modiﬁcation or no modiﬁcation. Both types of
mRNA reduced cellular protein translation; however, the
suppression of protein synthesis was greater with unmodi-
ﬁed RNA than with -containing RNA (Figure 1B).
PKR-activating poly(I:C) and non-activating poly(dC)
were used as controls. Mock transfected cells were
treated with the transfection reagent (lipofectin) only,
without nucleic acid.
Conventional in vitro transcribed mRNA activates PKR
To determine whether the inhibition of translation by un-
modiﬁed mRNA is mediated by PKR, in vitro transcribed
Figure 1. Translational inhibition by unmodiﬁed in vitro transcribed
mRNA. (A) In vitro transcribed mRNAs encoding Renilla luciferase
(Ren) and ﬁreﬂy luciferase (Luc) were synthesized with and without
 modiﬁcations then mixed (1:1 mass ratio) as indicated. The mixed
mRNA was complexed with lipofectin and added to HEK293T cells
seeded in 96-well plates (0.25mg RNA/well). Cells were lysed 4h after
transfection and dual luciferase measurements were performed in
aliquots (1/20th) of the lysates. Values presented are normalized to
cells transfected with Ren and Luc mRNAs when both contained 
modiﬁcations. Error bars indicate the standard error of n=3 samples.
(B) Unmodiﬁed or pseudouridine-containing RNA was delivered to
HEK293T cells by lipofection. Cells were subsequently incubated
with
35S-methionine/cysteine supplemented medium, lysed, and
proteins were TCA precipitated. Data are presented as percentage of
counts obtained from mock transfected cells. Data shown are mean
values from three independent experiments±SEM.
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puriﬁed PKR. Four diﬀerent mRNAs were tested: un-
modiﬁed and -modiﬁed mRNA, each with either a cap
or a triphosphate at their 50-end (50ppp). In vitro
transcribed mRNA with 50ppp and containing uridines
activated PKR to a greater extent than those containing
 (Figure 2). This reduced activation of PKR by
-containing transcripts is consistent with the previously
observed enhancement of in vitro translation from
-containing RNA in rabbit reticulocyte lysates (33).
Since the presence of 50ppp on short RNAs has previously
been shown to enhance the activation of PKR (12,13), it
was important to determine whether the 50ppp present on
long mRNAs also contributed to PKR activation. To
remove 50ppp, in vitro transcripts were capped
enzymatically (Supplementary Figure S1), which com-
pletely removed the 50ppp, and then tested. As Figure 2
demonstrates, the presence or absence of 50ppp on un-
modiﬁed and -modiﬁed transcripts did not signiﬁcantly
alter their ability to activate PKR. It has been shown that
a variety of nucleoside modiﬁcations in RNA can inﬂu-
ence the activation of RNA sensors (4,5,32); therefore, the
eﬀect of incorporating the modiﬁed nucleosides s2U,
5-methylcytidine (m5C), 6-methyladenosine (m6A) or
5-methyluridine (m5U) into mRNA was also analyzed.
mRNA containing s2U, m5C or m6A activated PKR to
a lesser extent than unmodiﬁed RNA, while RNA with
m5U activated PKR to the greatest extent
(Supplementary Figure S2).
Pseudouridine-containing mRNA does not
activate PKR in cells
Next, we investigated the impact of -containing mRNA
on PKR activation in the complex cellular environment.
Following control studies demonstrating that RNAs with
or without nucleoside modiﬁcation can be delivered to
cells with the same eﬃciency (data not shown), unmodiﬁed
or -containing mRNA was complexed with lipofectin
and delivered into HEK293T cells. PKR activation was
assessed by western blot using an antibody speciﬁc for
PKR phosphorylated on Thr446, a site at which phos-
phorylation is requisite for PKR activation (34).
Consistent with the results observed using puriﬁed PKR,
transfection of unmodiﬁed transcript induced PKR phos-
phorylation, which was dramatically reduced if the trans-
fected RNA contained  (Figure 3A). Similarly,
incorporation of s2U or m5C into RNA reduced the
level of PKR phosphorylation relative to that induced
by unmodiﬁed RNA, while m5U incorporation into
RNA enhanced PKR phosphorylation (Supplementary
Figure S3A). Incorporation of m6A into RNA also
enhanced PKR phosphorylation in cells, despite
reducing PKR activation in vitro.
Phosphorylation of eIF-2a, a substrate of PKR, was
induced in HEK293T cells by transfection with unmodi-
ﬁed RNA but not with -containing RNA (Figure 3B).
Incorporation of modiﬁed nucleosides other than  into
mRNA altered the phosphorylation of eIF-2a in direct
parallel to their alterations of PKR phosphorylation
(Supplementary Figure S3B).
Translation of unmodiﬁed mRNA is enhanced upon
inhibiting or eliminating PKR
Viral proteins C8L of swinepox and K3L of vaccinia are
inhibitors of PKR and have been shown to reverse
PKR-mediated inhibition of translation in mammalian
cells (35). Thus, to conﬁrm the role of PKR in the trans-
lational diﬀerences observed between uridine- and
Figure 2. Activation of puriﬁed PKR by in vitro transcribed RNA. Puriﬁed PKR was incubated with g-
32P-ATP and in vitro transcribed mRNA for
10min. Reaction products were separated by SDS–PAGE and imaged using phosphor storage radiography. Unmodiﬁed or -containing mRNAs
encoding ﬁreﬂy luciferase contained triphosphates (ppp) or cap at their 50-ends. Complete capping of RNA was achieved post-transcriptionally using
vaccinia capping enzyme. Concentration of mRNA in reactions was 3.1, 6.2, 12.5 and 25mg/ml. Quantiﬁed phosphorylation is presented as a bar
graph below each band. Values were normalized to those obtained with 25mg/ml uncapped, unmodiﬁed RNA. No RNA ( ) and 79 bp dsRNA were
used as negative and positive controls.
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K3L mutants: hyperactive K3L-H47R and inactive
K3L-Y76A (35,36). Based on the premise that PKR is
activated by in vitro transcribed mRNAs that contain
uridine but not by those with , inhibition of PKR
would be expected to increase the translation of unmodi-
ﬁed mRNA but to have no eﬀect on the translation of
-containing RNA. Indeed, in the presence of PKR in-
hibitors, the amount of translation increased from un-
modiﬁed transcripts but not from -modiﬁed transcripts
(Figure 4A).
Further evidence conﬁrming the role of PKR in sup-
pressing translation of unmodiﬁed mRNAs was obtaining
using mouse embryonic ﬁbroblasts (MEFs) derived from
PKR-knockout animals. In wild-type MEFs, translation
of -containing transcripts was 4–5-fold greater than that
of unmodiﬁed transcripts (Figure 4B). In PKR-deﬁcient
MEFs, however, the extent of translation of -modiﬁed
mRNA was not diﬀerent from that of unmodiﬁed mRNA.
Additionally, RNA transfection does not induce phos-
phorylation of eIF-2a in PKR-deﬁcient MEFs, as it does
in WT cells (Figure 4C). These results demonstrate that
the activity of PKR is necessary for the decreased trans-
lation of unmodiﬁed transcripts relative to -containing
transcripts.
Pseudouridine-containing mRNA is not bound by PKR
To test whether -modiﬁed mRNA is a competitive in-
hibitor of PKR, a 200-bp dsRNA known to activate PKR
was mixed with a 5–125-fold mass excess of -modiﬁed
RNA. All concentrations of -modiﬁed RNA tested failed
to inhibit the activation of PKR by the 200-bp dsRNA
(Figure 5). Similarly, a 125-fold mass excess of mRNA
containing s2U, m5C or m6A did not inhibit PKR activa-
tion by dsRNA (Figure S4). The results were the same
using lower mass excess, equal mass or equal molar
mixes (data not shown), demonstrating that RNAs con-
taining modiﬁed nucleosides are not competitive inhibitors
of PKR. The lack of PKR inhibition by transcripts con-
taining modiﬁed nucleosides suggests a lack of binding
between PKR and modiﬁed RNAs. To directly test
binding, biotinylated transcripts having 30-nt-long
poly(A) tails and containing either  or uridines were
mixed with HEK293T cell lysates, and complexes were
then precipitated using streptavidin-agarose beads.
Western blots of the precipitates indicated that PKR
bound to unmodiﬁed RNA, but bound poorly to
-modiﬁed RNA (Figure 6), consistent with reduced ac-
tivation of PKR by -containing RNA. By contrast,
poly(A)-binding protein (PABP) bound equally well to
both transcripts. These results indicate that unmodiﬁed
RNA, but not -modiﬁed RNA, binds to and activates
PKR.
DISCUSSION
We demonstrate that modiﬁed nucleosides in mRNA
reduce PKR activation and identify a mechanism by
which -incorporation in mRNA enhances translation
of the encoded protein. Our data show that conventional
in vitro transcribed RNA inhibits translation of reporter
and cellular mRNAs, in part through the activation of
PKR. However, this inhibitory activity is not induced by
-containing mRNA. Using multiple lines of investiga-
tion, our studies demonstrate that unmodiﬁed in vitro
transcribed mRNA activates PKR, resulting in phosphor-
ylation of eIF-2a and inhibition of translation.
Replacement of 50ppp with 50cap structure on the
mRNA does not substantially alter this PKR activation.
Examining translation in the context of PKR inhibitors
and in PKR-deﬁcient cells conﬁrmed that enhanced trans-
lation of -containing mRNA is a consequence of dimin-
ished PKR activation. Mechanistically, modiﬁed
nucleoside incorporation reduces RNA recognition by
PKR. This is supported by data demonstrating that
RNAs containing modiﬁed nucleosides do not inhibit
PKR activation by dsRNA and that PKR binds poorly
to -containing RNA.
PKR activation by unmodiﬁed RNA has a more
pronounced impact on translation of the transfected
reporter mRNA than on total cellular translation
(Figure 1). A similar local translation eﬀect has been
observed with PKR activation by IFN-g mRNA (19,37).
The pronounced local inhibition is likely due to the
kinetics of phosphorylation and dephosphorylation of
PKR. Activated PKR most dramatically inhibits local
translation because rapid dephosphorylation of PKR
limits the impact on more distant translation. Therefore,
translation of a PKR-activating mRNA is more severely
impacted than total cellular translation. Furthermore, the
Figure 3. PKR activation by in vitro transcribed mRNA in cells.
Unmodiﬁed or -containing in vitro transcribed ﬁreﬂy luciferase
mRNA was delivered to cells by lipofection. Following RNA transfec-
tion, cells were lysed at 4h (A) or at the indicated time (B), proteins
were separated by SDS–PAGE, and assayed for phosphorylation of
PKR (A) or eIF-2a (B) by western blotting. No RNA ( ), poly(dC)
and poly(I:C) were used as controls. Relative phosphorylation is
indicated below each gel lane, calculated as phosphorylated band
density divided by total band density and then normalized to the phos-
phorylation induced by unmodiﬁed RNA.
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duction in total protein synthesis suggests that there are
additional eﬀects on cellular translation which are not
mediated by PKR.
-containing RNA activates PKR more eﬀectively
in vitro as compared to in vivo (Figures 2 and 3). One
possible reason for this diﬀerence is that PKR activation
in vivo occurs in the presence of competing factors such as
phosphatases, components of the translational system and
other proteins aﬀecting the structure and accessibility of
the RNA to PKR. In contrast, in vitro assays lack such
competing factors that would limit or reverse PKR
phosphorylation.
Figure 4. Translation of in vitro transcribed mRNA in the absence of PKR activity. (A) HEK293T cells were transfected with plasmids encoding
protein inhibitors of PKR: swinepox C8L protein, wt vaccinia K3L, hyperactive K3L-H47R, inactive K3L-Y76A, or pG5 empty vector. Twenty-four
hours later, unmodiﬁed or -modiﬁed in vitro transcribed mRNAs encoding ﬁreﬂy luciferase were delivered by lipofection, and luciferase activity was
measured 4h later. Data were normalized to values obtained when cells were ﬁrst transfected with empty vector then with unmodiﬁed RNA.
Presented data are mean values from three replicates±SEM. (B) MEF cell lines derived from wild-type (WT) or transgenic mice that do not
express functional PKR (PKR
 / ) were transfected with unmodiﬁed or -containing in vitro transcribed mRNAs encoding ﬁreﬂy luciferase. Data
were normalized to values obtained when cells were transfected with unmodiﬁed RNA and expressed as fold increase in translation of -containing
mRNA over unmodiﬁed RNA. Values are from three replicate wells±SEM, and are representative of at least three independently performed
experiments. (C) WT and PKR
 /– MEF cells were transfected with unmodiﬁed or -containing in vitro transcribed mRNAs encoding ﬁreﬂy
luciferase, or mock transfected with no RNA (–). Cells were lysed 2h following RNA transfection; proteins were then separated by SDS–PAGE
and assayed for eIF-2a phosphorylation by western blotting. Relative phosphorylation is indicated above each gel lane, calculated as phosphorylated
band density divided by total band density and then normalized to the phosphorylation induced by unmodiﬁed RNA in wild-type cells. Absence of
PKR was also conﬁrmed by western blotting.
Figure 5. -containing mRNA does not inhibit PKR activation. An
activating 200 bp dsRNA was mixed with a 5–125-fold mass excess
of -containing in vitro transcribed ﬁreﬂy luciferase mRNA prior to
incubation with puriﬁed PKR. Reaction products were separated by
SDS–PAGE. Relative band densities are presented below each gel
lane and normalized to dsRNA only. Data shown are representative
of three independent experiments.
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complementary antisense transcript or long stretches
of self-complementarity, it contains many short ds
regions and other intramolecular secondary structures
(Figure S5). In addition to long perfectly dsRNA, PKR
is activated by RNA that contains either hairpins (9),
bulges, mismatched base-pairing (10), short internal
dsRNA regions (11) or unique structures naturally
present in selected cellular mRNAs (17–20). As previously
demonstrated for TLR3 (38), it is likely that the activation
of PKR by in vitro transcribed mRNA is due to the for-
mation of intra- and intermolecular secondary structures.
PKR is then activated upon binding to these structures,
similar to the classical dsRNA-mediated mechanism of
PKR activation. Nucleoside modiﬁcations inﬂuence base
pairing and secondary structure formation (39–46), which
likely contribute to their eﬀects on PKR activation.
Alterations to the shape of the helix formed and interrup-
tions to the minor groove, which is presumed to be the
principal location of PKR interaction with RNA
(32,47,48), are also likely to play signiﬁcant roles in
determining how each modiﬁed nucleoside will impact
RNA-mediated PKR activation.
Unlike short ssRNAs (12), PKR activation by long
in vitro transcribed mRNA is not dependent on the
presence of a 50-triphosphate, as mRNA containing
complete replacement of 50ppp with cap structure also ac-
tivates PKR (Figures 2 and S1). The diﬀerence between
these ﬁndings might reﬂect the amount of 50ppp in the
RNAs being compared. Forty-seven nucleotide-long
ssRNA induced 100-fold more PKR activation when the
50-end contained triphosphates (12), while our data did
not show any signiﬁcant eﬀect of removing the 50ppp
from 1976-nt-long mRNA, which contains  40-fold less
50ppp. Our ﬁnding is more consistent with the result
reported for 47-bp-long dsRNA wherein PKR activation
did not depend on 50ppp (12).
Previous reports indicate that PKR activation is altered
by the presence of modiﬁed nucleosides in homopolymeric
RNA (27,28,30) and short ssRNA and dsRNA (32). Our
data extend these ﬁndings by demonstrating that
incorporation of modiﬁed nucleosides into long in vitro
transcribed mRNA also alters activation of PKR, and
subsequent translation of the RNA. We observe substan-
tial PKR activation by in vitro transcribed mRNA, which
is reduced by incorporation of . Additionally, our
studies show reduced PKR activation by mRNA that
contains m5C, enhanced PKR activation by mRNA con-
taining m5U and elimination of PKR activation by
s2U-containing mRNAs. These results vary from those
obtained when testing PKR activation by short 47 nt
ssRNA: a low level of PKR activation by unmodiﬁed
RNA, which was dependent on the presence of a
50-triphosphate, and near-complete elimination of PKR
activation by incorporation of modiﬁed nucleosides (32).
However, when testing short 47-bp dsRNA, the eﬀects
observed were similar to those reported here: PKR acti-
vation by unmodiﬁed RNA, which is reduced by  incorp-
oration, increased by m5U incorporation, and eliminated
by s2U incorporation. This similarity to short dsRNA,
and dissimilarity to ssRNA, supports our model that
PKR activation by long in vitro transcribed mRNA is
due to regions of secondary structure formed within the
RNA and is independent of the 50-end.
Unlike the other nucleoside modiﬁcations tested, the
presence of m6A in mRNA impacted PKR activation dif-
ferently in vivo than in vitro. In vitro, mRNA containing
m6A activated PKR only moderately (Figure S2) whereas
in vivo, m6A-containing mRNA activated PKR more
potently than unmodiﬁed RNA (Figure S3). Although
the signiﬁcance of this observation is not fully understood,
the discrepancy may be explained by the presence of add-
itional factors in cells that facilitate increased ds formation
in m6A-containing mRNA in vivo.
Nucleic acids containing modiﬁed nucleosides can act as
antagonists of nucleic acid-sensing TLRs (49–52).
Therefore, we asked whether mRNAs containing
modiﬁed nucleosides inhibit activation of PKR by its
cognate ligand, dsRNA. PKR is still activated by
dsRNA in the presence of a 125-fold excess of mRNA
containing  or other modiﬁed nucleosides (s2U, m5C
or m6A), indicating that mRNAs containing modiﬁed nu-
cleosides are not inhibitors of PKR (Figures 5 and S4).
This extends previous data demonstrating that short
ssRNAs containing modiﬁed nucleosides do not inhibit
PKR (32). Furthermore, in cell lysates, RNA containing
 pulls down less PKR than RNA containing uridine
(Figure 6). This reduction in PKR binding is consistent
with prior in vitro data demonstrating small reductions in
PKR binding to short dsRNA and ssRNA that contain
modiﬁed nucleosides (32). From these data we conclude
that the mechanism of reduced PKR activation is reduced
recognition and binding to RNA containing modiﬁed
nucleosides.
It is possible that mRNAs with diﬀerent nucleoside
modiﬁcations have diﬀerent optimal concentrations for
activating PKR. Figures S2 and S3 indicate that none of
the modiﬁed nucleosides tested, with the exception of s2U,
completely eliminate PKR activation. Rather, each
modiﬁed nucleoside might alter the ability of RNA to
bind and activate PKR (Figure 6).
Figure 6. -containing mRNA does not pull-down PKR. Biotinylated
in vitro transcribed unmodiﬁed or -containing RNAs were incubated
with HEK293T cell lysates for 2h. The RNA and bound proteins were
pulled down using streptavidin-agarose beads. An aliquot of lysate that
was incubated only with beads but without RNA ( ) was also pro-
cessed. Aliquots of pull-down proteins as well as the supernatants were
separated by SDS–PAGE. PKR and PABP were detected by western
blotting. Relative band densities of PKR divided by PABP compared to
unmodiﬁed RNA are presented below each gel lane.
5890 Nucleic Acids Research, 2010,Vol.38, No. 17PKR plays an integral part in the cellular response to
viral RNA. However, mechanisms to avoid PKR activa-
tion by cellular RNAs are required, as constitutive PKR
activation and translational inhibition would obstruct
normal cellular function. Here, our data show that PKR
activation is reduced when RNAs contain nucleoside
modiﬁcations that are naturally present in many cellular
RNAs, including piRNA (53), snRNA, tRNA, mRNA
and rRNA (54). Activation of TLRs (4) and RIG-I (5)
is also inﬂuenced by modiﬁed nucleosides in RNA, and
most commonly RNA modiﬁcations decrease the im-
munogenicity of RNA. Together, these data support a
general interpretation that modiﬁed nucleosides supply a
pattern for diﬀerential recognition by RNA-binding
proteins. One purpose of common natural modiﬁcations
may be avoiding activation of PKR and other RNA
sensors by self-RNA.
Using mRNA for gene delivery has the beneﬁts of eﬃ-
cient transfection and rapid protein expression without the
risk of insertional mutagenesis. The potential of mRNA as
a delivery vehicle is enhanced further by incorporating
modiﬁed nucleosides that reduce host defense responses
initiated by PKR, TLRs, and RIG-I (4,5,32). We
recently reported the additional beneﬁt of increased trans-
lation from -containing mRNA (33). In vitro transcribed
mRNA is regularly delivered to cells in a research setting
and has entered clinical trials as a cancer vaccine. As the
interest in non-coding RNA continues, the delivery of
RNA is likely to continue expanding. In most cases,
activating PKR is an unwanted side eﬀect. High transla-
tion and low immunogenicity make mRNA containing 
or m5C applicable to express therapeutic proteins,
whereas s2U-modiﬁed RNA is best suited for applications
where avoiding nonspeciﬁc immunogenicity is desirable
but where translation is unnecessary (33), such as deliver-
ing antisense RNA (55) or stimulating RNA interference.
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